Literature DB >> 28477458

Surgical outcome of MRI-negative refractory extratemporal lobe epilepsy.

Jianguo Shi1, Nuria Lacuey2, Samden Lhatoo2.   

Abstract

OBJECTIVE: The aim of this study is to determine outcome of resective epilepsy surgery in MRI-negative extratemporal lobe epilepsy (MNETLE) patients who underwent invasive evaluations and to determine factors governing outcome.
METHODS: We studied 28 patients who underwent resective epilepsy surgery for MNETLE from August 2006 to November 2015, in whom complete follow-up information was available. Electro-clinical, pathological and surgical data were evaluated. 24 patients (82.8%) were explored with intracranial EEG (9 stereoelectroencephalography (SEEG), 7 subdural grids and 8 both). All patients were followed for at least 6 months.
RESULTS: During a mean follow up period of 32 [6-113] months, 13 (46.4%) patients became seizure-free (ILAE 1) and 18 (64.3%) had a good (ILAE 1, 2, 3) outcome. 21 (75.0%) patients had focal cortical dysplasia (FCD). Univariate analysis showed that more restricted (regional) interictal and ictal epileptiform discharges in surface EEG were significantly associated with seizure freedom (P=0.016 and P=0.024). Multivariate analysis confirmed that having ≥120 electrode contacts in the evaluation is an independent variable predicting seizure freedom (HR=4.283, 95% CI=1.342-13.676, P=0.014).
CONCLUSION: Invasive EEG is a powerful tool in the pre-surgical evaluation of patients with MNETLE. Invasive EEG implantation that include the irritative zone and EEG onset zone as indicated by surface EEG, as well as wider brain coverage predict seizure freedom, contingent upon a sound anatomo-electro-clinical hypothesis for implantation.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epilepsy surgery; Extratemporal epilepsy; HFOs; MRI-negative

Mesh:

Substances:

Year:  2017        PMID: 28477458     DOI: 10.1016/j.eplepsyres.2017.04.010

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  6 in total

Review 1.  Review: The past, present and future challenges in epilepsy-related and sudden deaths and biobanking.

Authors:  M Thom; M Boldrini; E Bundock; M N Sheppard; O Devinsky
Journal:  Neuropathol Appl Neurobiol       Date:  2018-02       Impact factor: 8.090

2.  Can histologically normal epileptogenic zone share common electrophysiological phenotypes with focal cortical dysplasia? SEEG-based study in MRI-negative epileptic patients.

Authors:  Stanislas Lagarde; Julia Scholly; Irina Popa; Maria Paola Valenti-Hirsch; Agnès Trebuchon; Aileen McGonigal; Mathieu Milh; Anke M Staack; Béatrice Lannes; Benoît Lhermitte; François Proust; Mustapha Benmekhbi; Didier Scavarda; Romain Carron; Dominique Figarella-Branger; Edouard Hirsch; Fabrice Bartolomei
Journal:  J Neurol       Date:  2019-05-04       Impact factor: 4.849

3.  Prognostic value of ictal onset patterns in postsurgical outcome of temporal lobe epilepsy.

Authors:  Jafar Mehvari-Habibabadi; Reza Basiratnia; Houshang Moein; Mohamad Zare; Majid Barakatain; Yahya Aghakhani; Nasim Tabrizi
Journal:  Iran J Neurol       Date:  2017-10-07

4.  Improved detection of focal cortical dysplasia using a novel 3D imaging sequence: Edge-Enhancing Gradient Echo (3D-EDGE) MRI.

Authors:  Erik H Middlebrooks; Chen Lin; Erin Westerhold; Lela Okromelidze; Prasanna Vibhute; Sanjeet S Grewal; Vivek Gupta
Journal:  Neuroimage Clin       Date:  2020-09-28       Impact factor: 4.881

5.  Surgical outcome and prognostic factors in epilepsy patients with MR-negative focal cortical dysplasia.

Authors:  Min Jae Seong; Su Jung Choi; Eun Yeon Joo; Young-Min Shon; Dae-Won Seo; Seung Bong Hong; Seung Chyul Hong
Journal:  PLoS One       Date:  2021-04-14       Impact factor: 3.240

6.  Multimodality Image Post-processing in Detection of Extratemporal MRI-Negative Cortical Dysplasia.

Authors:  Wen-Han Hu; Xiu Wang; Li-Na Liu; Xiao-Qiu Shao; Kai Zhang; Yan-Shan Ma; Lin Ai; Jun-Ju Li; Jian-Guo Zhang
Journal:  Front Neurol       Date:  2018-06-14       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.